{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:06:31Z","timestamp":1759741591968,"version":"3.37.3"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s11864-020-00807-y","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T14:22:16Z","timestamp":1610547736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Review of Pharmacologic Management in the Treatment of Mesothelioma"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9941-9893","authenticated-orcid":false,"given":"Eric P.","family":"Borrelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conor G.","family":"McGladrigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"issue":"Suppl 1","key":"807_CR1","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.21037\/tlcr.2019.11.11","volume":"9","author":"N Alpert","year":"2020","unstructured":"Alpert N, van Gerwen M, Taioli E. Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40\u00a0years after restricted\/banned asbestos use. Transl Lung Cancer Res. 2020;9(Suppl 1):S28\u201338.","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"807_CR2","first-page":"325","volume":"97","author":"CA Baldwin","year":"1982","unstructured":"Baldwin CA, Beaulieu HJ, Buchan RM, Johnson HH. Asbestos in Colorado schools. Public Health Rep. 1982;97(4):325\u201331.","journal-title":"Public Health Rep"},{"issue":"1","key":"807_CR3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0273-2300(91)90044-V","volume":"13","author":"M Corn","year":"1991","unstructured":"Corn M, Crump K, Farrar DB, Lee RJ, McFee DR. Airborne concentrations of asbestos in 71 school buildings. Regul Toxicol Pharmacol. 1991;13(1):99\u2013114.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"4","key":"807_CR4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/15298668091424735","volume":"41","author":"KF Irving","year":"1980","unstructured":"Irving KF, Alexander RG, Bavley H. Asbestos exposures in Massachusetts public schools. Am Ind Hyg Assoc J. 1980;41(4):270\u20136.","journal-title":"Am Ind Hyg Assoc J"},{"issue":"10","key":"807_CR5","first-page":"771","volume":"27","author":"NL Sprince","year":"1985","unstructured":"Sprince NL, Oliver LC, McLoud TC. Asbestos-related disease in plumbers and pipefitters employed in building construction. J Occup Med. 1985;27(10):771\u20135.","journal-title":"J Occup Med"},{"issue":"2","key":"807_CR6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1179\/oeh.1998.4.2.99","volume":"4","author":"JP Leigh","year":"1998","unstructured":"Leigh JP, Miller TR. Occupational illnesses within two national data sets. Int J Occup Environ Health. 1998;4(2):99\u2013113.","journal-title":"Int J Occup Environ Health"},{"key":"807_CR7","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/10937404.2016.1195323","volume":"19","author":"RA Lemen","year":"2016","unstructured":"Lemen RA. Mesothelioma from asbestos exposures: epidemiologic patterns and impact in the United States. J Toxicol Environ Health B Crit Rev. 2016;19:250\u201365.","journal-title":"J Toxicol Environ Health B Crit Rev"},{"issue":"11","key":"807_CR8","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3390\/ijerph14111302","volume":"14","author":"RA Lemen","year":"2017","unstructured":"Lemen RA, Landrigan PJ. Toward an asbestos ban in the United States. Int J Environ Res Public Health. 2017;14(11):1302.","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"807_CR9","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/annweh\/wxaa010","volume":"64","author":"A Rossner","year":"2020","unstructured":"Rossner A, Williams PRD, Mellas-Hulett E, Rahman MA. Analysis of historical worker exposures to respirable dust from talc mining and milling operations in Vermont. Ann Work Expo Health. 2020;64(4):416\u201329.","journal-title":"Ann Work Expo Health"},{"unstructured":"\u2022\u2022 Ettinger DS,Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, et al. Malignant pleural mesothelioma, version 1.2020, NCCN clinical practice guidelines in oncology. 2019. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpm.pdf. Accessed 17 May 2020. National Comprehensive Cancer Network (NCCN) treatment guidelines for mesothelioma.","key":"807_CR10"},{"issue":"6","key":"807_CR11","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ctrv.2011.10.006","volume":"38","author":"P Mirarabshahii","year":"2012","unstructured":"Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL. Diffuse malignant peritoneal mesothelioma--an update on treatment. Cancer Treat Rev. 2012;38(6):605\u201312.","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"807_CR12","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","volume":"27","author":"AS Tsao","year":"2009","unstructured":"Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol. 2009;27(12):2081\u201390.","journal-title":"J Clin Oncol"},{"issue":"8","key":"807_CR13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.15585\/mmwr.mm6608a3","volume":"66","author":"JM Mazurek","year":"2017","unstructured":"Mazurek JM, Syamlal G, Wood JM, Hendricks SA, Weston A. Malignant mesothelioma mortality - United States, 1999\u20132015. MMWR Morb Mortal Wkly Rep. 2017;66(8):214\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. 2019. Available at: https:\/\/seer.cancer.gov\/csr\/1975_2016\/. Accessed 23 May 2020.","key":"807_CR14"},{"unstructured":"SEER Cancer Stat Facts: Ovarian Cancer. National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html. Accessed 23 May 2020.","key":"807_CR15"},{"issue":"3","key":"807_CR16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/occmed\/kqg051","volume":"53","author":"AK Hilliard","year":"2003","unstructured":"Hilliard AK, Lovett JK, McGavin CR. The rise and fall in incidence of malignant mesothelioma from a British Naval Dockyard, 1979\u2013199. Occup Med (Lond). 2003;53(3):209\u201312.","journal-title":"Occup Med (Lond)"},{"issue":"7","key":"807_CR17","first-page":"718","volume":"34","author":"BP Lanphear","year":"1992","unstructured":"Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med. 1992;34(7):718\u201321.","journal-title":"J Occup Med"},{"key":"807_CR18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12995-016-0127-4","volume":"11","author":"K Tomasson","year":"2016","unstructured":"Tomasson K, Gudmundsson G, Briem H, Rafnsson V. Malignant mesothelioma incidence by nation-wide cancer registry: a population-based study. J Occup Med Toxicol. 2016;11:37.","journal-title":"J Occup Med Toxicol"},{"issue":"6","key":"807_CR19","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1183\/09031936.00000811","volume":"38","author":"AW Musk","year":"2011","unstructured":"Musk AW, Olsen N, Alfonso H, Reid A, Mina R, Franklin P, et al. Predicting survival in malignant mesothelioma. Eur Respir J. 2011;38(6):1420\u20134.","journal-title":"Eur Respir J"},{"unstructured":"American Cancer Society. Cancer facts & figures 2017: special section\u2014rare cancers in adults. https:\/\/tinyurl.com\/yb4joe3c. Accessed 24 May 2020.","key":"807_CR20"},{"doi-asserted-by":"publisher","unstructured":"Sirri E, Kieschke J, Vohmann C, et al. Survival of malignant mesothelioma and other rare thoracic cancers in Germany and the United States: a population-based study [published online ahead of print, 2020 Feb 18]. Int J Cancer. 2020. https:\/\/doi.org\/10.1002\/ijc.32931.","key":"807_CR21","DOI":"10.1002\/ijc.32931"},{"issue":"9","key":"807_CR22","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/ajim.22206","volume":"56","author":"R Diandini","year":"2013","unstructured":"Diandini R, Takahashi K, Park EK, Jiang Y, Movahed M, Vinh G, et al. Potential years of life lost (PYLL) caused by asbestos-related diseases in the world. Am J Ind Med. 2013;56(9):993\u20131000.","journal-title":"Am J Ind Med"},{"issue":"8","key":"807_CR23","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/oemed-2011-100462","volume":"69","author":"LJ Lee","year":"2012","unstructured":"Lee LJ, Chang YY, Liou SH, Wang JD. Estimation of benefit of prevention of occupational cancer for comparative risk assessment: methods and examples. Occup Environ Med. 2012;69(8):582\u20136.","journal-title":"Occup Environ Med"},{"doi-asserted-by":"crossref","unstructured":"Metintas S, Ak G, Metintas M. Potential years of life and productivity loss due to malignant mesothelioma in Turkey. Arch Environ Occup Health. 2020;75(8):464\u2013470","key":"807_CR24","DOI":"10.1080\/19338244.2020.1747380"},{"issue":"Suppl 5","key":"807_CR25","doi-asserted-by":"crossref","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","volume":"26","author":"P Baas","year":"2015","unstructured":"Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v31\u20139.","journal-title":"Ann Oncol"},{"issue":"13","key":"807_CR26","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","volume":"36","author":"HL Kindler","year":"2018","unstructured":"Kindler HL, Ismaila N, Armato SG 3rd, Bueno R, Hesdorffer M, Jahan T, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(13):1343\u201373.","journal-title":"J Clin Oncol"},{"issue":"6","key":"807_CR27","first-page":"E254","volume":"5","author":"N van Zandwijk","year":"2013","unstructured":"van Zandwijk N, Clarke C, Henderson D, Musk AW, Fong K, Nowak A, et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013;5(6):E254\u2013307.","journal-title":"J Thorac Dis"},{"unstructured":"Medicare Part B Drug Average Sales Price. CMS.gov Centers for Medicare & Medicaid Services. https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Part-B-Drugs\/McrPartBDrugAvgSalesPrice\/index.html. Accessed 27 May 2020.","key":"807_CR28"},{"doi-asserted-by":"publisher","unstructured":"Health Policy Brief: Medicare Part B,\u201d Health Affairs, August 10, 2017. https:\/\/doi.org\/10.1377\/hpb2017.6","key":"807_CR29","DOI":"10.1377\/hpb2017.6"},{"issue":"1","key":"807_CR30","doi-asserted-by":"crossref","first-page":"e8933","DOI":"10.1371\/journal.pone.0008933","volume":"5","author":"JJ Sacco","year":"2010","unstructured":"Sacco JJ, Botten J, Macbeth F. The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLoS One. 2010;5(1):e8933.","journal-title":"PLoS One"},{"unstructured":"Alimta (Pemetrexed) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.","key":"807_CR31"},{"unstructured":"Cisplatin [package insert]. Durham, NC: Accord Healthcare Inc.; 2019.","key":"807_CR32"},{"unstructured":"Pemfexy (Pemetrexed) [package insert]. Woodcliff Lake, NJ: Eagle Pharmaceuticals; 2020.","key":"807_CR33"},{"issue":"14","key":"807_CR34","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636\u201344.","journal-title":"J Clin Oncol"},{"issue":"7","key":"807_CR35","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","volume":"3","author":"A Santoro","year":"2008","unstructured":"Santoro A, O\u2019Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona\u00efve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol. 2008;3(7):756\u201363.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"807_CR36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.lungcan.2006.09.023","volume":"55","author":"CK Obasaju","year":"2007","unstructured":"Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, et al. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy na\u00efve patients with malignant pleural mesothelioma: outcomes of an expanded access program. Lung Cancer. 2007;55(2):187\u201394.","journal-title":"Lung Cancer"},{"issue":"10026","key":"807_CR37","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomized, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405\u201314.","journal-title":"Lancet."},{"issue":"1","key":"807_CR38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1524-4733.2007.00209.x","volume":"11","author":"A Cordony","year":"2008","unstructured":"Cordony A, Le Reun C, Smala A, Symanowski JT, Watkins J. Cost-effectiveness of pemetrexed plus cisplatin: malignant pleural mesothelioma treatment in UK clinical practice. Value Health. 2008;11(1):4\u201312.","journal-title":"Value Health"},{"issue":"1","key":"807_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11010","volume":"11","author":"Y Dundar","year":"2007","unstructured":"Dundar Y, Bagust A, Dickson R, Dodd S, Green J, Haycox A, et al. Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation. Health Technol Assess. 2007;11(1):1\u201390.","journal-title":"Health Technol Assess"},{"unstructured":"National Institute for Health and Clinical Excellence (NICE). Updated guide to the methods of technology appraisal. London: NICE; 2013. Available at: https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781. Accessed September 28, 2020.","key":"807_CR40"},{"unstructured":"Rind DM, Agboola F, Kumar VM, Borrelli E, Pearson SD. Unsupported price increase report: 2019 assessment. Institute for Clinical and Economic Review. 2019. https:\/\/icer-review.org\/wp-content\/uploads\/2019\/01\/ICER_UPI_Final_Report_and_Assessment_110619.pdf. Accessed 28 May 2020.","key":"807_CR41"},{"unstructured":"Carboplatin [package insert]. Sunrise, FL: Cipla USA; 2018.","key":"807_CR42"},{"issue":"5","key":"807_CR43","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1470-2045(00)00325-9","volume":"2","author":"NJ Curtin","year":"2001","unstructured":"Curtin NJ, Hughes AN. Pemetrexed disodium, a novel antifolate with multiple targets. Lancet Oncol. 2001;2(5):298\u2013306.","journal-title":"Lancet Oncol"},{"issue":"9","key":"807_CR44","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","volume":"24","author":"GL Ceresoli","year":"2006","unstructured":"Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006;24(9):1443\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"807_CR45","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/annonc\/mdm501","volume":"19","author":"B Castagneto","year":"2008","unstructured":"Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol. 2008;19(2):370\u20133.","journal-title":"Ann Oncol"},{"issue":"11","key":"807_CR46","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s12094-013-1015-3","volume":"15","author":"EE Habib","year":"2013","unstructured":"Habib EE, Fahmy ES. Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens. Clin Transl Oncol. 2013;15(11):965\u20138.","journal-title":"Clin Transl Oncol"},{"issue":"11","key":"807_CR47","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA, O\u2019Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748\u201356.","journal-title":"J Clin Oncol"},{"issue":"1","key":"807_CR48","doi-asserted-by":"crossref","first-page":"11129","DOI":"10.1038\/s41598-019-47560-3","volume":"9","author":"R Schwameis","year":"2019","unstructured":"Schwameis R, Postl M, Bekos C, Hefler L, Reinthaller A, Seebacher V, et al. Prognostic value of serum creatine level in patients with vulvar cancer. Sci Rep. 2019;9(1):11129.","journal-title":"Sci Rep"},{"unstructured":"Avastin (Bevacizumab) [package insert]. South San Francisco, CA: Genentech, Inc.; 2019.","key":"807_CR49"},{"unstructured":"Zirabev (Bevacizumab-bvzr) [package insert]. New York, NY: Pfizer, Inc.; 2020.","key":"807_CR50"},{"unstructured":"Mvasi (Bevacizumab-awwb) [package insert]. Thousand Oaks, CA: Amgen Inc.; 2019.","key":"807_CR51"},{"issue":"3","key":"807_CR52","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.lungcan.2012.05.111","volume":"77","author":"JE Dowell","year":"2012","unstructured":"Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, et al. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer. 2012;77(3):567\u201371.","journal-title":"Lung Cancer"},{"issue":"19","key":"807_CR53","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1158\/1078-0432.CCR-18-2860","volume":"25","author":"G Eberst","year":"2019","unstructured":"\u2022 Eberst G, Anota A, Scherpereel A, Mazieres J, Margery J, Greillier L, et al. Health-related quality of life impact from adding bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS IFCT-GFPC-0701 phase III trial. Clin Cancer Res. 2019;25(19):5759\u201365. Health-related quality of life results from a randomized controlled trial comparing the addition of bevacizumab to pemetrexed and cisplatin.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"807_CR54","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/bjc.2013.368","volume":"109","author":"GL Ceresoli","year":"2013","unstructured":"Ceresoli GL, Zucali PA, Mencoboni M, Botta M, Grossi F, Cortinovis D, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer. 2013;109(3):552\u20138.","journal-title":"Br J Cancer"},{"key":"807_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.05.012","volume":"110","author":"M Zhan","year":"2017","unstructured":"Zhan M, Zheng H, Xu T, Yang Y, Li Q. Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial. Lung Cancer. 2017;110:1\u20136.","journal-title":"Lung Cancer"},{"issue":"3","key":"807_CR56","doi-asserted-by":"crossref","first-page":"A153","DOI":"10.1016\/j.jval.2016.03.1610","volume":"19","author":"J Malacan","year":"2016","unstructured":"Malacan J, Carlson JJ. Cost-effectiveness analysis of addition of bevacizumab to a standard chemotherapy doublet (pemetrexed+ cisplatin) in patients with malignant pleural mesothelioma. Value Health. 2016;19(3):A153.","journal-title":"Value Health"},{"issue":"22","key":"807_CR57","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1161\/CIR.0000000000000042","volume":"129","author":"JL Anderson","year":"2014","unstructured":"Anderson JL, Heidenreich PA, Barnett PG, Creager MA, Fonarow GC, et al. ACC\/AHA Task Force on Performance Measures; ACC\/AHA Task Force on Practice Guidelines. ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129(22):2329\u201345.","journal-title":"Circulation."},{"unstructured":"Institute for Clinical and Economic Review. Overview of the ICER value assessment framework and update for 2017\u20132019. Available at: http:\/\/icer-review.org\/wp-content\/uploads\/2017\/06\/ICER-value-assessment-framework-Updated-050818.pdf. Accessed 29 Sept 2020.","key":"807_CR58"},{"issue":"9","key":"807_CR59","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796\u20137.","journal-title":"N Engl J Med"},{"unstructured":"Imfinzi (Durvalumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.","key":"807_CR60"},{"issue":"9","key":"807_CR61","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","volume":"21","author":"AK Nowak","year":"2020","unstructured":"Nowak AK, Lesterhuis WJ, Kok PS, Brown C, Hughes BG, Karikios DJ, et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 2020;21(9):1213\u201323.","journal-title":"Lancet Oncol"},{"issue":"15S","key":"807_CR62","doi-asserted-by":"crossref","first-page":"9003","DOI":"10.1200\/JCO.2020.38.15_suppl.9003","volume":"38","author":"PM Forde","year":"2020","unstructured":"Forde PM, Sun Z, Anagnostou V, Kindler HL, Purcell WT, Goulart BHL, et al. PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)\u2014A PrECOG LLC study. J Clin Oncol. 2020;38(15S):9003.","journal-title":"J Clin Oncol"},{"issue":"7","key":"807_CR63","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/JTO.0b013e31817c73ec","volume":"3","author":"P Taylor","year":"2008","unstructured":"Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, et al. Single-agent pemetrexed for chemona\u00efve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol. 2008;3(7):764\u201371.","journal-title":"J Thorac Oncol"},{"issue":"8","key":"807_CR64","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1200\/JCO.2003.06.122","volume":"21","author":"GV Scagliotti","year":"2003","unstructured":"Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol. 2003;21(8):1556\u201361.","journal-title":"J Clin Oncol"},{"issue":"10","key":"807_CR65","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","volume":"26","author":"J Jassem","year":"2008","unstructured":"Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008;26(10):1698\u2013704.","journal-title":"J Clin Oncol"},{"unstructured":"Gemcitabine [package insert]. Durham, NC: Accord Healthcare Inc.; 2019.","key":"807_CR66"},{"issue":"1","key":"807_CR67","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.1999.17.1.25","volume":"17","author":"MJ Byrne","year":"1999","unstructured":"Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999;17(1):25\u201330.","journal-title":"J Clin Oncol"},{"issue":"5","key":"807_CR68","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/sj.bjc.6600505","volume":"87","author":"AK Nowak","year":"2002","unstructured":"Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002;87(5):491\u20136.","journal-title":"Br J Cancer"},{"issue":"3","key":"807_CR69","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/sj.bjc.6600118","volume":"86","author":"JM van Haarst","year":"2002","unstructured":"van Haarst JM, Baas P, Manegold C, Schouwink JH, Burgers JA, de Bruin HG, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer. 2002;86(3):342\u20135.","journal-title":"Br J Cancer"},{"issue":"3","key":"807_CR70","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/01.coc.0000144852.75613.56","volume":"28","author":"B Castagneto","year":"2005","unstructured":"Castagneto B, Zai S, Dongiovanni D, Muzio A, Bretti S, Numico G, et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol. 2005;28(3):223\u20136.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"807_CR71","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.lungcan.2007.09.018","volume":"60","author":"SR Kalmadi","year":"2008","unstructured":"Kalmadi SR, Rankin C, Kraut MJ, Jacobs AD, Petrylak DP, Adelstein DJ, et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer. 2008;60(2):259\u201363.","journal-title":"Lung Cancer"},{"issue":"20","key":"807_CR72","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","volume":"30","author":"HL Kindler","year":"2012","unstructured":"Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012;30(20):2509\u201315.","journal-title":"J Clin Oncol"},{"unstructured":"Navelbine (vinorelbine) [package insert]. Parsippany, NJ: Pierre Fabre Pharmaceuticals, Inc.; 2020.","key":"807_CR73"},{"issue":"23","key":"807_CR74","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1200\/JCO.2000.18.23.3912","volume":"18","author":"JP Steele","year":"2000","unstructured":"Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol. 2000;18(23):3912\u20137.","journal-title":"J Clin Oncol"},{"issue":"9625","key":"807_CR75","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(08)60727-8","volume":"371","author":"MF Muers","year":"2008","unstructured":"Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, et al. MS01 Trial Management Group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomized trial. Lancet. 2008;371(9625):1685\u201394.","journal-title":"Lancet"},{"issue":"1","key":"807_CR76","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","volume":"63","author":"J Stebbing","year":"2009","unstructured":"Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 2009;63(1):94\u20137.","journal-title":"Lung Cancer"},{"issue":"3","key":"807_CR77","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","volume":"84","author":"MG Zauderer","year":"2014","unstructured":"Zauderer MG, Kass SL, Woo K, Sima CS, Ginsberg MS, Krug LM. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer. 2014;84(3):271\u20134.","journal-title":"Lung Cancer"},{"unstructured":"Opdivo (nivolumab) [package insert insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2020.","key":"807_CR78"},{"unstructured":"Yervoy (ipilimumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2020.","key":"807_CR79"},{"issue":"2","key":"807_CR80","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","volume":"20","author":"A Scherpereel","year":"2019","unstructured":"\u2022\u2022 Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, D\u00f4 P, Bylicki O, et al. French Cooperative Thoracic Intergroup. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomized, non-comparative, phase 2 trial. Lancet Oncol. 2019;20(2):239\u201353. A large multi-center phase 2 randomized trial assessing the safety and efficacy of nivolumab as well as nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma.","journal-title":"Lancet Oncol"},{"issue":"3","key":"807_CR81","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","volume":"7","author":"MJ Disselhorst","year":"2019","unstructured":"\u2022 Disselhorst MJ, Quispel-Janssen J, Lalezari F, Monkhorst K, de Vries JF, van der Noort V, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019;7(3):260\u201370. Results from a single-center, single-arm phase 2 clinical trial assessing the safety and efficacy of ipilimumab and nivolumab in patients with recurrent malignant pleural mesothelioma.","journal-title":"Lancet Respir Med"},{"unstructured":"Baas P, Scherpereel A, Nowak A, Fujimoto N, Peters S, Tsao A, et al. First-line nivolumab + ipilimumab vs chemotherapy in unresectable malignant pleural mesothelioma: CHECKMATE 743. 2020 World Conference on Lung Cancer Singapore Conference Abstract Presidential Symposium: 3\u20134. Available at: https:\/\/wclc2020.iaslc.org\/wp-content\/uploads\/2020\/08\/Abstracts-Virtual-Presidential-Symposium.pdf. Accessed 24 Sept 2020.","key":"807_CR82"},{"unstructured":"Bristol Myers Squibb announces positive topline result from pivotal phase 3 trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) vs. chemotherapy in previously untreated malignant pleural mesothelioma. Published April 20, 2020. https:\/\/news.bms.com\/press-release\/corporatefinancial-news\/bristol-myers-squibb-announces-positive-topline-result-pivotal. Accessed 26 May 2020.","key":"807_CR83"},{"unstructured":"Keytruda (Pembrolizumab) [package insert]. Whitehouse Station, NJ: Merck & Co, Inc.; 2020.","key":"807_CR84"},{"unstructured":"ClinicalTrials.gov. A pilot window-of-opportunity study of the anti-PD-1 antibody pembrolizumab in patients with resectable malignant pleural mesothelioma. (NCT02707666). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02707666. Accessed 27 May 2020.","key":"807_CR85"},{"unstructured":"ClinicalTrials.gov. Pembrolizumab in combination with chemotherapy and image-guided surgery for malignant pleural mesothelioma (MPM). (NCT03760575). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03760575. Accessed 27 May 2020.","key":"807_CR86"},{"issue":"5","key":"807_CR87","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","volume":"18","author":"EW Alley","year":"2017","unstructured":"\u2022 Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomized, open-label, phase 1b trial. Lancet Oncol. 2017;18(5):623\u201330. Preliminary data of pembrolizumab in patients with mesothelioma from a open-label, phase 1b, non-randomized clinical trial.","journal-title":"Lancet Oncol"},{"issue":"11","key":"807_CR88","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","volume":"13","author":"Y Metaxas","year":"2018","unstructured":"Metaxas Y, Rivalland G, Mauti LA, Klingbiel D, Kao S, Schmid S, et al. Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. J Thorac Oncol. 2018;13(11):1784\u201391.","journal-title":"J Thorac Oncol"},{"issue":"15S","key":"807_CR89","doi-asserted-by":"crossref","first-page":"e21094","DOI":"10.1200\/JCO.2020.38.15_suppl.e21094","volume":"38","author":"ME Marmarelis","year":"2020","unstructured":"Marmarelis ME, Wang X, Roshkovan L, Walker S, McNulty S, Ciunci CA, et al. Real-world outcomes of pembrolizumab in peritoneal mesothelioma. J Clin Oncol. 2020;38(15S):e21094.","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"807_CR90","doi-asserted-by":"crossref","first-page":"S322","DOI":"10.21037\/jtd.2017.12.88","volume":"10","author":"L Calabr\u00f2","year":"2018","unstructured":"Calabr\u00f2 L, Rossi G, Maio M. New horizons from immunotherapy in malignant pleural mesothelioma. J Thorac Dis. 2018;10(Suppl 2):S322\u201332.","journal-title":"J Thorac Dis"},{"key":"807_CR91","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fonc.2020.00343","volume":"10","author":"L Cantini","year":"2020","unstructured":"Cantini L, Hassan R, Sterman DH, Aerts JGJV. Emerging treatments for malignant pleural mesothelioma: where are we heading? Front Oncol. 2020;10:343.","journal-title":"Front Oncol"},{"issue":"3","key":"807_CR92","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","volume":"19","author":"A Scherpereel","year":"2018","unstructured":"Scherpereel A, Wallyn F, Albelda SM, Munck C. Novel therapies for malignant pleural mesothelioma. Lancet Oncol. 2018;19(3):e161\u201372.","journal-title":"Lancet Oncol"},{"issue":"5","key":"807_CR93","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1007\/s10637-015-0282-y","volume":"33","author":"SF Jones","year":"2015","unstructured":"Jones SF, Siu LL, Bendell JC, Cleary JM, Razak AR, Infante JR, et al. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Investig New Drugs. 2015;33(5):1100\u20137.","journal-title":"Investig New Drugs"},{"issue":"4","key":"807_CR94","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1080\/15384047.2017.1416937","volume":"19","author":"R Kanteti","year":"2018","unstructured":"Kanteti R, Mirzapoiazova T, Riehm JJ, Dhanasingh I, Mambetsariev B, Wang J, et al. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biol Ther. 2018;19(4):316\u201327.","journal-title":"Cancer Biol Ther"},{"issue":"10","key":"807_CR95","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","volume":"37","author":"DA Fennell","year":"2019","unstructured":"Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, et al. Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND-A double-blind, randomized, phase II study. J Clin Oncol. 2019;37(10):790\u20138.","journal-title":"J Clin Oncol"},{"unstructured":"ClinicalTrials.gov. Pembrolizumab + defactinib in pleural mesothelioma. (NCT04201145). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04201145. Accessed 1 June 2020.","key":"807_CR96"},{"unstructured":"ClinicalTrials.gov. Study of FAK (defactinib) and PD-1 (pembrolizumab) inhibition in advanced solid malignancies (FAK-PD1). (NCT02758587). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02758587. Accessed 1 June 2020.","key":"807_CR97"},{"unstructured":"Rubraca (rucaparib) [package insert]. Boulder, CO: Clovis Oncology Inc.; 2020.","key":"807_CR98"},{"unstructured":"Lynparza (olaparib) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LLP; 2020.","key":"807_CR99"},{"issue":"4","key":"807_CR100","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00280-017-3401-y","volume":"80","author":"G Srinivasan","year":"2017","unstructured":"Srinivasan G, Sidhu GS, Williamson EA, Jaiswal AS, Najmunnisa N, Wilcoxen K, et al. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. Cancer Chemother Pharmacol. 2017;80(4):861\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"807_CR101","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12885-019-5314-0","volume":"19","author":"S Borchert","year":"2019","unstructured":"Borchert S, Wessolly M, Schmeller J, Mairinger E, Kollmeier J, Hager T, et al. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro. BMC Cancer. 2019;19(1):108.","journal-title":"BMC Cancer"},{"issue":"5","key":"807_CR102","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jtho.2020.01.012","volume":"15","author":"D Rathkey","year":"2020","unstructured":"Rathkey D, Khanal M, Murai J, Zhang J, Sengupta M, Jiang Q, et al. Sensitivity of mesothelioma cells to PARP inhibitors is not dependent on BAP1 but is enhanced by temozolomide in cells with high-Schlafen 11 and low-O6-methylguanine-DNA methyltransferase expression. J Thorac Oncol. 2020;15(5):843\u201359.","journal-title":"J Thorac Oncol"},{"unstructured":"ClinicalTrials.gov. Mesothelioma stratified therapy (MiST): a multi-drug phase II trial in malignant mesothelioma (MiST). (NCT03654833). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03654833. Accessed 3 June 2020.","key":"807_CR103"},{"issue":"15S","key":"807_CR104","doi-asserted-by":"crossref","first-page":"9057","DOI":"10.1200\/JCO.2020.38.15_suppl.9057","volume":"38","author":"DA Fennell","year":"2020","unstructured":"Fennell DA, Darlison L, Wells-Jordan P, Richards CJ, Gaba A, Poile C, et al. MiST1: A phase IIa trial of rucaparib in patients harboring BAP1\/BRCA1 deficient relapsed malignant mesothelioma. J Clin Oncol. 2020;38(15S):9057.","journal-title":"J Clin Oncol"},{"unstructured":"ClinicalTrials.gov. Olaparib in people with malignant mesothelioma. (NCT03531840). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03531840. Accessed 3 June 2020.","key":"807_CR105"},{"issue":"15S","key":"807_CR106","doi-asserted-by":"crossref","first-page":"9054","DOI":"10.1200\/JCO.2020.38.15_suppl.9054","volume":"38","author":"R Hassan","year":"2020","unstructured":"Hassan R, Mian I, Wagner C, Mallory Y, Agra M, Padiernos E, et al. Phase II study of olaparib in malignant mesothelioma (MM) to correlate efficacy with germline and somatic mutations in DNA repair genes. J Clin Oncol. 2020;38(15S):9054.","journal-title":"J Clin Oncol"},{"unstructured":"Tecentriq (Atezolizumab) [package insert]. South San Francisco, CA: Genentech, Inc.; 2019.","key":"807_CR107"},{"issue":"10031","key":"807_CR108","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909\u201320.","journal-title":"Lancet."},{"issue":"10030","key":"807_CR109","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomized controlled trial. Lancet. 2016;387(10030):1837\u201346.","journal-title":"Lancet."},{"issue":"3","key":"807_CR110","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1164\/rccm.201608-1755CI","volume":"196","author":"LA Lievense","year":"2017","unstructured":"Lievense LA, Sterman DH, Cornelissen R, Aerts JG. Checkpoint blockade in lung cancer and mesothelioma. Am J Respir Crit Care Med. 2017;196(3):274\u201382.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"807_CR111","doi-asserted-by":"crossref","first-page":"212","DOI":"10.21037\/tlcr.2017.04.01","volume":"6","author":"EW Alley","year":"2017","unstructured":"Alley EW, Katz SI, Cengel KA, Simone CB 2nd. Immunotherapy and radiation therapy for malignant pleural mesothelioma. Transl Lung Cancer Res. 2017;6(2):212\u20139.","journal-title":"Transl Lung Cancer Res"},{"issue":"2","key":"807_CR112","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11864-019-0613-x","volume":"20","author":"PM Forde","year":"2019","unstructured":"Forde PM, Scherpereel A, Tsao AS. Use of immune checkpoint inhibitors in mesothelioma. Curr Treat Options in Oncol. 2019;20(2):18.","journal-title":"Curr Treat Options in Oncol"},{"issue":"15S","key":"807_CR113","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1200\/JCO.2020.38.15_suppl.9013","volume":"38","author":"KP Raghav","year":"2020","unstructured":"Raghav KP, Overman MJ, Liu S, Willett A, Royal RE, Malpica A, et al. A phase II trial of atezolizumab and bevacizumab in patients with relapsed\/refractory and unresectable malignant peritoneal mesothelioma. J Clin Oncol. 2020;38(15S):9013.","journal-title":"J Clin Oncol"},{"unstructured":"ClinicalTrials.gov. A study of atezolizumab in unresectable or advanced malignant pleural mesothelioma. (NCT03786419). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03786419. Accessed 4 June 2020.","key":"807_CR114"},{"unstructured":"ClinicalTrials.gov. BEAT-meso: bevacizumab and atezolizumab in malignant pleural mesothelioma (BEAT-meso). (NCT03762018). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03762018. Accessed 4 June 2020.","key":"807_CR115"},{"unstructured":"Verzenio (Abemaciclib) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.","key":"807_CR116"},{"issue":"15S","key":"807_CR117","doi-asserted-by":"crossref","first-page":"e24326","DOI":"10.1200\/JCO.2018.36.15_suppl.e24326","volume":"36","author":"S Matsumoto","year":"2018","unstructured":"Matsumoto S, Fukuda A, Nakamichi T, Nakamura A, Kuroda A, Hashimoto M, et al. CDK4\/6 inhibitor and radiation therapy in malignant pleural mesothelioma. J Clin Oncol. 2018;36(15S):e24326.","journal-title":"J Clin Oncol"},{"issue":"8","key":"807_CR118","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1158\/1535-7163.MCT-16-0821","volume":"16","author":"J Cooper","year":"2017","unstructured":"Cooper J, Xu Q, Zhou L, Pavlovic M, Ojeda V, Moulick K, et al. Combined inhibition of NEDD8-activating enzyme and mTOR suppresses NF2 loss-driven tumorigenesis. Mol Cancer Ther. 2017;16(8):1693\u2013704.","journal-title":"Mol Cancer Ther"},{"unstructured":"ClinicalTrials.gov. Pevonedistat alone and in combination with chemotherapy in patients with mesothelioma. (NCT03319537). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03319537. Accessed 29 Sept 2020.","key":"807_CR119"},{"unstructured":"Adcetris (Brentuximab) [package insert]. Bothell, WA: Seattle Genetics; 2018.","key":"807_CR120"},{"issue":"15S","key":"807_CR121","doi-asserted-by":"crossref","first-page":"e18526","DOI":"10.1200\/jco.2013.31.15_suppl.e18526","volume":"31","author":"A Dowlati","year":"2013","unstructured":"Dowlati A, Dabir S, Kresak A, Yang M, Wildey G. Use of CD30 expression in human malignant mesothelioma as a novel therapeutic target. J Clin Oncol. 2013;31(15S):e18526.","journal-title":"J Clin Oncol"},{"issue":"5","key":"807_CR122","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.ijrobp.2014.08.035","volume":"90","author":"SI Jalal","year":"2014","unstructured":"Jalal SI, Einhorn L, Shapiro GI, Hilton J, Wheler J, Dowlati A, et al. Brentuximab vedotin in patients with CD30+ mesothelioma: mesothelioma, thymic malignancies, and other thoracic malignancies. Int J Radiat Oncol Biol Phys. 2014;90(5):S8.","journal-title":"Int J Radiat Oncol Biol Phys"},{"unstructured":"ClinicalTrials.gov. Brentuximab vedotin in treating patients with CD30+ malignant mesothelioma that cannot be removed by surgery. (NCT03007030). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03007030. Accessed 29 Sept 2020.","key":"807_CR123"},{"issue":"4","key":"807_CR124","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s10637-019-00768-6","volume":"37","author":"JP Sharman","year":"2019","unstructured":"Sharman JP, Wheler JJ, Einhorn L, Dowlati A, Shapiro GI, Hilton J, et al. A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors. Investig New Drugs. 2019;37(4):738\u201347.","journal-title":"Investig New Drugs"},{"unstructured":"Cyramza (ramucirumab) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.","key":"807_CR125"},{"issue":"6","key":"807_CR126","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/annonc\/mdv144","volume":"26","author":"EG Chiorean","year":"2015","unstructured":"Chiorean EG, Hurwitz HI, Cohen RB, Schwartz JD, Dalal RP, Fox FE, et al. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Ann Oncol. 2015;26(6):1230\u20137.","journal-title":"Ann Oncol"},{"unstructured":"ClinicalTrials.gov. Phase II nivolumab and ramucirumab for patients with previously-treated mesothelioma. (NCT03502746). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03502746. Accessed 29 Sept 2020.","key":"807_CR127"},{"issue":"15S","key":"807_CR128","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1200\/JCO.2020.38.15_suppl.9004","volume":"38","author":"M Pagano","year":"2020","unstructured":"Pagano M, Ceresoli GL, Zucali PA, Pasello G, Garassino MC, Grosso F, et al. Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): results of Italian Rames study. J Clin Oncol. 2020;38(15S):9004.","journal-title":"J Clin Oncol"},{"issue":"2","key":"807_CR129","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11864-011-0154-4","volume":"12","author":"AJ Kaufman","year":"2011","unstructured":"Kaufman AJ, Flores RM. Surgical treatment of malignant pleural mesothelioma. Curr Treat Options in Oncol. 2011;12(2):201\u201316.","journal-title":"Curr Treat Options in Oncol"},{"issue":"1","key":"807_CR130","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.athoracsur.2018.07.081","volume":"107","author":"S Kim","year":"2019","unstructured":"Kim S, Bull DA, Garland L, Khalpey Z, Stea B, Yi S, et al. Is there a role for cancer-directed surgery in early-stage sarcomatoid or biphasic mesothelioma? Ann Thorac Surg. 2019;107(1):194\u2013201.","journal-title":"Ann Thorac Surg"},{"issue":"8","key":"807_CR131","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1097\/JTO.0b013e3182208e3f","volume":"6","author":"D Rice","year":"2011","unstructured":"Rice D, Rusch V, Pass H, Asamura H, Nakano T, Edwards J, et al. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol. 2011;6(8):1304\u201312.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"807_CR132","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S1470-2045(11)70307-2","volume":"12","author":"W Weder","year":"2011","unstructured":"Weder W, Stahel RA, Baas P, Dafni U, de Perrot M, McCaughan BC, et al. The MARS feasibility trial: conclusions not supported by data. Lancet Oncol. 2011;12(12):1093\u20135.","journal-title":"Lancet Oncol"},{"issue":"1","key":"807_CR133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2017.08.003","volume":"125","author":"M Ashton","year":"2017","unstructured":"Ashton M, O\u2019Rourke N, Currie S, Rimner A, Chalmers A. The role of radical radiotherapy in the management of malignant pleural mesothelioma: a systematic review. Radiother Oncol. 2017;125(1):1\u201312.","journal-title":"Radiother Oncol"},{"issue":"2","key":"807_CR134","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/JTO.0b013e31827740f0","volume":"8","author":"DR Gomez","year":"2013","unstructured":"Gomez DR, Hong DS, Allen PK, Welsh JS, Mehran RJ, Tsao AS, et al. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013;8(2):238\u201345.","journal-title":"J Thorac Oncol"},{"issue":"23","key":"807_CR135","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","volume":"34","author":"A Rimner","year":"2016","unstructured":"Rimner A, Zauderer MG, Gomez DR, Adusumilli PS, Parhar PK, Wu AJ, et al. Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma. J Clin Oncol. 2016;34(23):2761\u20138.","journal-title":"J Clin Oncol"},{"key":"807_CR136","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.lungcan.2020.05.032","volume":"146","author":"AB Thompson","year":"2020","unstructured":"Thompson AB, Quinn TJ, Siddiqui ZA, Almahariq MF, Grills IS, Stevens CW. Addition of radiotherapy to surgery and chemotherapy improves survival in localized malignant pleural mesothelioma: a Surveillance, Epidemiology, and End Results (SEER) study [published online ahead of print, 2020 May 30]. Lung Cancer. 2020;146:120\u20136. https:\/\/doi.org\/10.1016\/j.lungcan.2020.05.032.","journal-title":"Lung Cancer"},{"issue":"3","key":"807_CR137","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1378\/chest.108.3.754","volume":"108","author":"C Boutin","year":"1995","unstructured":"Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest. 1995;108(3):754\u20138.","journal-title":"Chest."},{"issue":"1","key":"807_CR138","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.bjc.6601957","volume":"91","author":"S Bydder","year":"2004","unstructured":"Bydder S, Phillips M, Joseph DJ, Cameron F, Spry NA, DeMelker Y, et al. A randomized trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer. 2004;91(1):9\u201310.","journal-title":"Br J Cancer"},{"issue":"8","key":"807_CR139","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(16)30095-X","volume":"17","author":"AO Clive","year":"2016","unstructured":"Clive AO, Taylor H, Dobson L, Wilson P, de Winton E, Panakis N, et al. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomized controlled trial. Lancet Oncol. 2016;17(8):1094\u2013104.","journal-title":"Lancet Oncol"},{"issue":"1","key":"807_CR140","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.radonc.2007.05.022","volume":"84","author":"N O\u2019Rourke","year":"2007","unstructured":"O\u2019Rourke N, Garcia JC, Paul J, Lawless C, McMenemin R, Hill J. A randomized controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol. 2007;84(1):18\u201322.","journal-title":"Radiother Oncol"},{"issue":"2","key":"807_CR141","doi-asserted-by":"crossref","first-page":"e0190257","DOI":"10.1371\/journal.pone.0190257","volume":"13","author":"SA Stewart","year":"2018","unstructured":"Stewart SA, Clive AO, Maskell NA, Penz E. Evaluating quality of life and cost implications of prophylactic radiotherapy in mesothelioma: health economic analysis of the SMART trial. PLoS One. 2018;13(2):e0190257.","journal-title":"PLoS One"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-00807-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-020-00807-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-00807-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T22:44:49Z","timestamp":1613688289000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-020-00807-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":141,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["807"],"URL":"https:\/\/doi.org\/10.1007\/s11864-020-00807-y","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"type":"print","value":"1527-2729"},{"type":"electronic","value":"1534-6277"}],"subject":[],"published":{"date-parts":[[2021,1,12]]},"assertion":[{"value":"20 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"14"}}